Biotricity (BTCY)
搜索文档
Biotricity (BTCY) - 2024 Q4 - Annual Report
2024-06-27 01:58
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the fiscal year ended: March 31, 2024 Commission File Number: 000-56074 (Exact name of registrant as specified in its charter) If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Sectio ...
Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks Investment Research· 2024-04-04 14:56
BTCY股价走势 - Biotricity Inc. (BTCY) 最近股价走势熊市,过去两周下跌了15.3%[1] - 锤子图形的形成表明股价可能很快会见到趋势反转,因为多头可能已经控制了价格,帮助其找到支撑[1] - 锤子图形被认为是接近底部的技术指标,可能会减轻卖压[2] BTCY盈利预期 - 华尔街分析师对该公司的盈利预期普遍看涨,增强了其趋势反转的前景[2] - BTCY最近的盈利预期修订呈上升趋势,这是基本面上的一个看涨指标[7] - 过去30天,BTCY今年的一致EPS预期增长了21.8%,分析师普遍认为公司将报告比之前预测更好的盈利[8] 锤子图形特点 - 锤子图形是蜡烛图中的一种常见价格模式,通常在下跌趋势中形成[3] - 锤子蜡烛可以出现在任何时间框架上,被短期和长期投资者使用[5] - 锤子图形的强度取决于其在图表上的位置,应与其他多头指标一起使用[6] BTCY排名和评级 - BTCY目前的Zacks Rank为2(买入),这意味着它在我们基于盈利预期修订和EPS惊喜趋势排名的4000多只股票中处于前20%[9]
Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY)
Zacks Investment Research· 2024-03-14 13:51
Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...
Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research· 2024-03-07 18:01
Biotricity Inc. (BTCY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Si ...
Biotricity (BTCY) - 2024 Q3 - Earnings Call Transcript
2024-02-22 00:02
财务数据和关键指标变化 - 第三季度收入同比增长21%,达到2.97百万美元 [18] - 毛利率提升至73%,较上年同期的57%大幅提高 [19] - 技术服务费收入占总收入的93%,同比增长23% [30][31] - 设备销售收入占总收入的6.5%,达到193,000美元 [32] - 经营亏损缩小至620万美元,同比减少400万美元 [28] - 净亏损同比改善,从4.7百万美元降至3百万美元 [29] 各条业务线数据和关键指标变化 - 公司的核心产品Biotres和Bioflux设备销售保持强劲增长 [16] - 公司监测和诊断了超过25万名患者,记录了超过5000亿次心跳数据 [9][17] - 公司正在开发基于AI的心脏云平台,用于预测性监测和早期干预 [8][46][47] 各个市场数据和关键指标变化 - 公司已进入35个州,覆盖数千名心脏病专科医生和数百家医疗中心 [20] - 公司与主要的集团采购组织(GPO)建立了合作关系,预计可覆盖80%的美国医院 [26] - 公司正在积极拓展海外市场,已获得其他国家的监管批准 [33] 公司战略和发展方向及行业竞争 - 公司正在转型为以订阅服务为主的业务模式,提高收入质量和可预测性 [18] - 公司调整销售团队结构,采用"猎手-农夫"模式,提高销售效率 [23][39][40][41][42][43] - 公司聚焦大型医疗机构和GPO客户,拓展更大的市场机会 [26][41] - 公司持续优化成本结构,将一些研发项目推迟至2025年 [27][48][49][50] - 公司看好心脏远程监护领域的长期发展前景 [34] 管理层对经营环境和未来前景的评论 - 公司正朝着实现正现金流和盈利的目标稳步前进 [7][12][27][34] - 公司的技术和产品在全球范围内具有广泛应用前景 [33] - 公司看好心脏远程监护市场的发展趋势,有信心保持市场领先地位 [34] - 公司正在加快推进心脏AI云平台的开发,预计将在明年中期实现商业化 [46][47] 问答环节重要的提问和回答 问题1 **Ben Haynor 提问** 询问公司调整销售团队结构后的效率提升情况 [38][39][40] **Waqaas Al-Siddiq 回答** 公司采用"猎手-农夫"模式后,销售团队更加专注,效率有所提升,但具体数字难以量化 [39][40][41][42][43] 问题2 **Michael Davin 提问** 询问公司心脏AI云平台的开发进度和商业化时间表 [45][46][47][48] **Waqaas Al-Siddiq 回答** 公司正在分析5000亿次心跳数据,预计今年底提交FDA申请,明年中期实现商业化 [46][47] 问题3 **Michael Davin 提问** 询问设备销售增长是来自现有客户还是新客户 [51][52] **Waqaas Al-Siddiq 回答** 设备销售增长来自现有客户的持续增长以及新客户的开发 [52][53]
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research· 2024-02-21 00:21
Biotricity Inc. (BTCY) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.07%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $0.44, delivering a surprise of -29.41%.Over the last four quarters, the company has surpass ...
Biotricity (BTCY) - 2024 Q3 - Quarterly Report
2024-02-19 16:00
● Fair value of derivative liabilities In determining the fair values of the derivative liabilities from the conversion and redemption features, the Company used MonteCarlo and lattice models with the following assumptions: dividend yields, volatility, risk-free rate and the remaining expected life. Changes in those assumptions and inputs could in turn impact the fair value of the derivative liabilities and can have a material impact on the reported loss and comprehensive loss for the applicable reporting p ...
Biotricity (BTCY) - 2024 Q2 - Earnings Call Transcript
2023-11-15 02:25
分组1 - 公司本季度继续取得双位数销售增长,经常性技术费收入、设备销售和毛利率均呈现正增长,同时公司保持成本控制以取得现金流正转和盈利 [8][10] - 公司推出新的在线商城,提供用户友好的集成购物体验,进一步提升分销销售和简化销售运营 [9] - 公司销售团队扩大了地理覆盖范围,截至9月30日在32个州拥有客户,同比收入增长21.4% [10] - 公司毛利率从上年同期的54%提升至69%,销售费用和研发费用也有所下降,净亏损同比减少20% [10][11][30][33] 分组2 - 公司专注于预防性医疗的远程监测解决方案,在诊断和诊后领域均有创新 [13][14][15] - 公司的Biosphere平台和Biocare应用程序获得了广泛关注,正在利用人工智能技术开发一系列预测性监测工具 [16][17] - 公司与亚马逊和谷歌等主要企业建立了合作伙伴关系,利用他们的基础设施和技术提升自身的心脏监测能力 [17][18][59][60] - 公司最新推出的Biotres Pro产品具有离线数据存储和蜂窝网络备份功能,进一步增强了远程心脏监测的能力 [41][46][47] 问答环节重要的提问和回答 问题1 **Michael Davin 提问** Biotres Pro的蜂窝网络备份功能如何帮助患者和诊所 [45] **Waqaas Al-Siddiq 回答** 该功能可以在设备连接中断的情况下继续上传数据,避免之前需要手动充电和上传数据的问题,提升了患者和诊所的使用体验 [46][47] 问题2 **Michael Davin 提问** 公司目前在哪些细分市场看到最大需求 [48] **Waqaas Al-Siddiq 回答** 公司目前在独立心脏诊所和医院市场都有需求,未来将在两个市场间保持平衡发展 [49][50] 问题3 **Michael Davin 提问** 公司如何量化提升患者依从性的成效 [55] **Waqaas Al-Siddiq 回答** 公司正在通过患者使用应用程序的数据来分析患者依从性,未来将发布相关影响报告 [56]
Biotricity (BTCY) - 2024 Q2 - Quarterly Report
2023-11-13 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BTCY The NASDAQ Stock Market LLC Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the period from ______________ ...
Biotricity (BTCY) - 2024 Q1 - Earnings Call Transcript
2023-08-16 01:13
Biotricity (NASDAQ:BTCY) Q1 2024 Earnings Conference Call August 15, 2023 4:30 PM ET Debra Chen – Investor Relations Conference Call Participants Operator Debra Chen Before beginning the companyÂ's formal remarks, IÂ'd like to remind listeners that todayÂ's discussion may contains forward-looking statements that reflect managementÂ's current views with respect to future events. Any such statements are subject to risks and uncertainties that can cause actual results to differ materially from those projected ...